A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study

作者：Yasui Hirofumi^*; Muro Kei; Shimada Yasuhiro; Tsuji Akihito; Sameshima Shinichi; Baba Hideo; Satoh Taroh; Denda Tadamichi; Ina Kenji; Nishina Tomohiro; Yamaguchi Kensei; Esaki Taito; Tokunaga Shinya; Kuwano Hiroyuki; Boku Narikazu; Komatsu Yoshito; Watanabe Masahiko; Hyodo Ichinosuke; Morita Satoshi; Sugihara Kenichi

来源：Journal of Cancer Research and Clinical Oncology, 2015, 141(1): 153-160.

DOI：10.1007/s00432-014-1783-3

• Colorectal cancer
• FIRIS
• Irinotecan
• IRIS
• S-1

The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint. The overall survival (OS) data were immature at the time of the primary analysis.
Between 30 January 2006 and 29 January 2008, 426 patients with mCRC who failed in first-line chemotherapy were randomly assigned to receive either FOLFIRI or IRIS. After the primary analysis, the follow-up survey was cut off on 29 July 2010, and the final OS data were analysed.
With a median follow-up of 39.2 months, the median OS was 17.4 months in the FOLFIRI group and 17.8 months in the IRIS group [hazard ratio (HR) 0.900; 95 % confidence interval (CI) 0.728-1.112]. In the pre-planned subgroup of patients who received prior chemotherapy containing oxaliplatin, the median OS was 12.7 months in the FOLFIRI group and 15.3 months in the IRIS group (HR 0.755; 95 % CI 0.580-0.983).
IRIS is non-inferior to FOLFIRI for OS as second-line chemotherapy for mCRC. IRIS can be an option for second-line chemotherapy of mCRC. (ClinicalTrials.gov Number: NCT00284258).

• 出版日期2015-1